Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India
Abstract
Purpose: The purpose of this study is to evaluate the safety and effectiveness of brolucizumab intravitreal injections (IVI) in Indian patients with neovascular age-related macular degeneration (nAMD).
Methods: This prospective, interventional, single-arm, open-label phase IV study included 105 treatment-naïve nAMD patients prescribed brolucizumab as per the local prescribing information, across ten centers. The treatment period consisted of 56 weeks, including loading doses at Weeks 0, 4, and 8, followed by disease activity assessment at Week 16, evaluating patients for 12-weekly (q12w) or 8-weekly (q8w) dosing. The primary endpoint was the incidence and characteristics of treatment-emergent adverse events (TEAEs) during 56 weeks. Secondary endpoints included changes in effectiveness variables - visual acuity, intraretinal fluid (IRF), subretinal fluid (SRF), and central subfield thickness (CST), at 16 and 56 weeks.
Results: Post-Week 16, 74 (70.5%) patients received q12w, and 27 (25.7%) patients received q8w dosing. Four TEAEs were reported in three (2.9%) patients, all ocular: vitritis in two patients who were discontinued and retinal vasculitis and uveitis in one patient who completed the study. No TEAEs were severe, and there were no serious adverse events. Best corrected visual acuity (BCVA) improved significantly by seven letters (95% CI: 5.0, 10.0) at Week 16 and by 15 letters (95% CI: 10.0, 18.0) at Week 56 ( P < 0.0001 for both). All anatomical parameters also…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 16 participants or records.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.